ST-Segment Recovery and Prognosis in Patients With ST-Elevation Myocardial Infarction Reperfused by Prehospital Combination Fibrinolysis, Prehospital Initiated Facilitated Percutaneous Coronary Intervention, or Primary Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 98, Issue 9, 2006, Pages 1132-1139

  Thiele, Holger ^a   Scholz, Marius ^a   Engelmann, Lothar ^a   Storch, Wulf Hinrich ^b   Hartmann, Andreas ^c   Dimmel, Gerald ^a   Pfeiffer, Dietrich ^a   Schuler, Gerhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Retfungsamt Leipzig   (Germany)

^c Klinikum St Georg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN; RETEPLASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; EMERGENCY CARE; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; ST SEGMENT ELEVATION; STROKE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; GERMANY; HEART CONDUCTION SYSTEM; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33750979568     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.05.044     Document Type: Article

References (27)

1. Thiele H., Engelmann L., Elsner K., Kappl M.J., Storch W.H., Rahimi K., Hartmann A., Pfeiffer D., Kneissl G.D., Schneider D., et al. Comparison of prehospital combination-fibrinolysis plus conventional care with prehospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 26 (2005) 1956-1963
2. Schröder R., Dissmann R., Brüggemann T., Wegscheider K., Linderer T., Tebbe U., and Neuhaus K.L. Extent of early ST-segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 24 (1994) 384-391
3. Ito H., Maruyama A., and Iwakura K. Clinical implications of the 'no reflow' phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93 (1996) 223-228
4. Santoro G.M., Valenti R., Buonamici P., Bolognese L., Cerisano G., Moschi G., Trapani M., Antoniucci D., and Fazzini P.F. Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty. Am J Cardiol 82 (1998) 932-937
5. Schröder K., Wegscheider K., Zeymer U., Tebbe U., and Schröder R. Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction. Lancet 358 (2001) 1479-1486
6. van 't Hof A.W., Liem A., de Boer M.J., and Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 350 (1997) 615-619
7. Angeja B.G., Gunda M., Murphy S.A., Sobel B.E., Rundle A.C., Syed M., Asfour A., Borzak S., Gourlay S.G., Barron H.V., et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 105 (2002) 282-285
8. Dong J., Ndrepepa G., Schmitt C., Mehilli J., Schmieder S., Schwaiger M., Schomig A., and Kastrati A. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. Circulation 105 (2002) 2946-2949
9. Schröder R., Zeymer U., Wegscheider K., and Neuhaus K.L. Comparison of the predictive value of ST segment elevation resolution at 90 and 180 min after start of streptokinase in acute myocardial infarction. A substudy of the hirudin for improvement of thrombolysis (HIT)-4 study. Eur Heart J 20 (1999) 1563-1571
10. Zeymer U., Schroeder R., Maching T., and Neuhaus K.L. Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction. Am Heart J 146 (2003) 686-691
11. de Lemos J.A., Antman E.M., Gibson C.M., McCabe C.H., Giugliano R.P., Murphy S.A., Coulter S.A., Anderson K., Scherer J., Frey M.J., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Circulation 101 (2000) 239-243
12. Anderson R.D., White H.D., Ohman E.M., Wagner G.S., Krucoff M.W., Armstrong P.W., Weaver W.D., Gibler W.B., Stebbins A.L., Califf R.M., and Topol E.J. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. Am Heart J 144 (2002) 81-88
13. Baran K.W., Nguyen M., McKendall G.R., Lambrew C.T., Dykstra G., Palmeri S.T., Gibbons R.J., Borzak S., Sobel B.E., Gourlay S.G., et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 104 (2001) 2778-2783
14. Mahaffey K.W., Granger C.B., Nicolau J.C., Ruzyllo W., Weaver W.D., Theroux P., Hochman J.S., Filloon T.G., Mojcik C.F., Todaro T.G., and Armstrong P. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction. Circulation 108 (2003) 1176-1183
15. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101 (2000) 2788-2794
16. Brodie B., Stuckey T.D., Hansen C., VerSteeg D.S., Muncy D.B., Moore S., Gupta N., and Downey W.E. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 95 (2005) 343-348
17. McLaughlin M.G., Stone G.W., Aymong E., Gardner G., Mehran R., Lansky A.J., Grines C.L., Tcheng J.E., Cox D.A., Stuckey T., et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 44 (2004) 1215-1223
18. Zeymer U., Zahn R., Schiele R., Jansen W., Girth E., Gitt A., Seidl K., Schröder R., Schneider S., and Senges J. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized Integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 26 (2005) 1971-1977
19. Gyöngyösi M., Domanovits H., Benzer W., Haugk M., Heinisch B., Sodeck G., Hödl R., Gaul G., Bonner G., Wojta J., et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion-results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 25 (2004) 2125-2133
20. Cutlip D.E., Ricciardi M.J., Ling F.S., Carrozza J., Joseph P., Dua V., Garringer J., Giri S., and Caputo R.P. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 92 (2003) 977-980
21. Zorman S., Zorman D., and Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 90 (2002) 533-536
22. Chesebro J.H., Knatterud G.L., Roberts R., Borer J., Cohen L.S., Dalen J., Dodge H.T., Francis C.K., Hillis D., and Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76 (1987) 142-154
23. Nallamothu B.K., Bates E.R., Herrin J., Wang Y., Bradley E.H., and Krumholz H.M. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States. Circulation 111 (2005) 761-767
24. Cannon C.P., Gibson C.M., Lambrew C.T., Shoultz D.A., Levy D., French W.J., Gore J.M., Weaver W.D., Rogers W.J., and Tiefenbrunn A.J. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 283 (2000) 2941-2947
25. Kastrati A., Mehilli J., Schlotterbeck K., Dotzer F., Dirschinger J., Schmitt C., Nekolla S.G., Seyfarth M., Markwardt C., Clermont G., et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention. JAMA 291 (2004) 947-954
26. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006) 569-578
27. Ellis S.G., Armstrong P., Betriu A., Brodie B., Herrmann H., Montalescot G., Neumann F.J., Smith J.J., and Topol E. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. Am Heart J 147 (2004) 684-689